As of 2014, Simmons Hanly Conroy lawyers are no longer accepting Chantix cases. The following is for informational purposes only.
Chantix is used for withdrawals from smoking cessation, while going from nicotine dependency and continuing through nicotine recovery. Chantix, known by the generic name varenicline, works by blocking the effect of nicotine on the brain. When a person quits smoking, the lower levels of dopamine and other brain chemicals causes the symptoms of nicotine withdrawal. Chantix combats these withdrawal symptoms by stimulating the release of low levels of dopamine and other brain chemicals. Chantix also blocks the brain’s nicotine receptors, so future cigarettes do not have the same effect, thus potentially stifling a relapse to regular smoking.
Dangers Associated with Chantix
In early 2008, FDA officials acknowledged receiving troubling reports from Chantix patients throughout the United States. These reports included 34 cases of suicide and nearly 420 reports of suicidal thoughts, behaviors and completed suicides.
As of July 2009, the most serious reports to the FDA involving Chantix were:
- 98 suicides in Chantix users
- 188 attempted suicides in Chantix users
On July 1, 2009, the FDA required varenicline to carry the most severe safety warning, the black box label. Dangerous Chantix side effects include:
- depressed mood
- unusual behaviors
- thinking about suicide
- attempting suicide
United States District Court Judge Inge Johnson appointed Shareholders Jayne Conroy and Clint Fisher to leadership positions in the Chantix Products Liability Litigation pending in the Northern District of Alabama. Mr. Fisher was a member of the Plaintiffs’ Steering Committee, and Ms. Conroy was Co-Lead State Liaison Counsel. Shareholder David Miceli served on the National Plaintiff Steering Committee for the Chantix Multidistrict Litigation.
I appreciate all that the Simmons firm has done for me. I’m thrilled with the result they got for me and want to say thanks to everyone there.